Enhancing Treatment for Patients With GIST: Michael Heinrich, MD

Because gastrointestinal stromal tumor (GIST) has an estimated incidence of 3,300 to 6,000 new cases per year in the United States, comprising less than 1% of all gastrointestinal tumors, the rarity of this tumor type can make it more challenging for oncologists and other members of the cancer care team to stay up to date on the latest treatments. Michael C. Heinrich, MD, lead investigator of the phase 1 NAVIGATOR trial, recently spoke with i3 Health about the FDA's approval of avapritinib (Ayva...
Continue reading

How Genetic Testing Results Impact Breast Cancer Treatment: Allison Kurian, MD, MSc

​With our ever-growing understanding of mutations that increase cancer risk and the rise of targeted treatments such as poly (ADP-ribose) polymerase (PARP) inhibitors that are indicated for specific mutations, the use of germline genetic testing for patients with breast cancer has increased significantly in recent years. How are these test results affecting patients' treatment? In a population-based cohort study published recently published in JAMA Oncology, Allison W. Kurian, MD, MSc, and colle...
Continue reading

The Current State of CRPC Management With Judd W. Moul, MD, FACS

In the past decade, much progress has been made in the management of castration-resistant prostate cancer (CRPC), with numerous new agents improving outcomes in patients with this disease. However, many challenges still remain. In this interview with i3 Health, Judd W. Moul, MD, FACS, Professor of Urologic Surgery at the Duke School of Medicine, discusses strategies that community oncologists and urologists can utilize to determine the best treatment for their patients. He also discusses the rol...
Continue reading

Avapritinib for PDGFRA Exon 18-Mutated GIST: Michael Heinrich, MD

Up to 10% of patients with gastrointestinal stromal tumor (GIST) harbor platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutations, which have been linked to resistance to standard GIST therapies. The FDA's recent approval of avapritinib (AyvakitTM, Blueprint Medicines) for adults with unresectable or metastatic GIST with PDGFRA exon 18 mutations has given these patients a highly promising treatment option. In this interview, Michael C. Heinrich, MD, lead investigator of the phase ...
Continue reading

Pembrolizumab for Non-Muscle Invasive Bladder Cancer With Ashish Kamat, MD, MBBS

The FDA recently approved pembrolizumab (Keytruda®, Merck) for the treatment of patients with high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG) therapy. The approval was based on Keynote 057 (NCT02625961), a phase 2 trial in which pembrolizumab produced a complete response rate of 41% in patients with this disease. In this interview with i3 Health, Ashish Kamat, MD, MBBS, Professor of Urologic Oncology (Surgery) and Cancer Research at MD Anderson...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.